163 related articles for article (PubMed ID: 20598534)
1. Synthesis and SAR of azolopyrimidines as potent and selective dipeptidyl peptidase-4 (DPP4) inhibitors for type 2 diabetes.
Brigance RP; Meng W; Fura A; Harrity T; Wang A; Zahler R; Kirby MS; Hamann LG
Bioorg Med Chem Lett; 2010 Aug; 20(15):4395-8. PubMed ID: 20598534
[TBL] [Abstract][Full Text] [Related]
2. (2S,3S)-3-Amino-4-(3,3-difluoropyrrolidin-1-yl)-N,N-dimethyl-4-oxo-2-(4-[1,2,4]triazolo[1,5-a]-pyridin-6-ylphenyl)butanamide: a selective alpha-amino amide dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Edmondson SD; Mastracchio A; Mathvink RJ; He J; Harper B; Park YJ; Beconi M; Di Salvo J; Eiermann GJ; He H; Leiting B; Leone JF; Levorse DA; Lyons K; Patel RA; Patel SB; Petrov A; Scapin G; Shang J; Roy RS; Smith A; Wu JK; Xu S; Zhu B; Thornberry NA; Weber AE
J Med Chem; 2006 Jun; 49(12):3614-27. PubMed ID: 16759103
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Evaluation of Novel [1,2,4]Triazolo[5,1-c][1,2,4]-triazines and Pyrazolo[5,1-c][1,2,4]triazines as Potential Antidiabetic Agents.
Rusinov VL; Sapozhnikova IM; Bliznik AM; Chupakhin ON; Charushin VN; Spasov AA; Vassiliev PM; Kuznetsova VA; Rashchenko AI; Babkov DA
Arch Pharm (Weinheim); 2017 May; 350(5):. PubMed ID: 28393419
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, evaluation and molecular docking of thiazolopyrimidine derivatives as dipeptidyl peptidase IV inhibitors.
Sharma M; Gupta M; Singh D; Kumar M; Kaur P
Chem Biol Drug Des; 2012 Dec; 80(6):918-28. PubMed ID: 22943413
[TBL] [Abstract][Full Text] [Related]
5. The highly potent and selective dipeptidyl peptidase IV inhibitors bearing a thienopyrimidine scaffold effectively treat type 2 diabetes.
Deng J; Peng L; Zhang G; Lan X; Li C; Chen F; Zhou Y; Lin Z; Chen L; Dai R; Xu H; Yang L; Zhang X; Hu W
Eur J Med Chem; 2011 Jan; 46(1):71-6. PubMed ID: 21106276
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors.
Zhang L; Su M; Li J; Ji X; Wang J; Li Z; Li J; Liu H
Chem Biol Drug Des; 2013 Feb; 81(2):198-207. PubMed ID: 22994702
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of hetero-aromatic moieties substituted pyrrole-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors.
Ji X; Su M; Wang J; Deng G; Deng S; Li Z; Tang C; Li J; Li J; Zhao L; Jiang H; Liu H
Eur J Med Chem; 2014 Mar; 75():111-22. PubMed ID: 24531224
[TBL] [Abstract][Full Text] [Related]
8. Identification of 3-aminomethyl-1,2-dihydro-4-phenyl-1-isoquinolones: a new class of potent, selective, and orally active non-peptide dipeptidyl peptidase IV inhibitors that form a unique interaction with Lys554.
Banno Y; Miyamoto Y; Sasaki M; Oi S; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Tsubotani S; Tani A; Funami M; Tawada M; Yamamoto Y; Aertgeerts K; Yano J; Maezaki H
Bioorg Med Chem; 2011 Aug; 19(16):4953-70. PubMed ID: 21764322
[TBL] [Abstract][Full Text] [Related]
9. (3R)-4-[(3R)-3-Amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(2,2,2-trifluoroethyl)-1,4-diazepan-2-one, a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Biftu T; Feng D; Qian X; Liang GB; Kieczykowski G; Eiermann G; He H; Leiting B; Lyons K; Petrov A; Sinha-Roy R; Zhang B; Scapin G; Patel S; Gao YD; Singh S; Wu J; Zhang X; Thornberry NA; Weber AE
Bioorg Med Chem Lett; 2007 Jan; 17(1):49-52. PubMed ID: 17055272
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent, selective, and orally bioavailable quinoline-based dipeptidyl peptidase IV inhibitors targeting Lys554.
Maezaki H; Banno Y; Miyamoto Y; Moritoh Y; Asakawa T; Kataoka O; Takeuchi K; Suzuki N; Ikedo K; Kosaka T; Sasaki M; Tsubotani S; Tani A; Funami M; Yamamoto Y; Tawada M; Aertgeerts K; Yano J; Oi S
Bioorg Med Chem; 2011 Aug; 19(15):4482-98. PubMed ID: 21741847
[TBL] [Abstract][Full Text] [Related]
11. Identification of dipeptidyl peptidase IV inhibitors: virtual screening, synthesis and biological evaluation.
Xing J; Li Q; Zhang S; Liu H; Zhao L; Cheng H; Zhang Y; Zhou J; Zhang H
Chem Biol Drug Des; 2014 Sep; 84(3):364-77. PubMed ID: 24674599
[TBL] [Abstract][Full Text] [Related]
12. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
Gupta RC; Chhipa L; Mandhare AB; Zambad SP; Chauthaiwale V; Nadkarni SS; Dutt C
Bioorg Med Chem Lett; 2009 Sep; 19(17):5021-5. PubMed ID: 19643608
[TBL] [Abstract][Full Text] [Related]
13. A time-resolved fluorescence probe for dipeptidyl peptidase 4 and its application in inhibitor screening.
Kawaguchi M; Okabe T; Terai T; Hanaoka K; Kojima H; Minegishi I; Nagano T
Chemistry; 2010 Dec; 16(45):13479-86. PubMed ID: 20938933
[TBL] [Abstract][Full Text] [Related]
14. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
Ammirati MJ; Andrews KM; Boyer DD; Brodeur AM; Danley DE; Doran SD; Hulin B; Liu S; McPherson RK; Orena SJ; Parker JC; Polivkova J; Qiu X; Soglia CB; Treadway JL; VanVolkenburg MA; Wilder DC; Piotrowski DW
Bioorg Med Chem Lett; 2009 Apr; 19(7):1991-5. PubMed ID: 19275964
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 6-(aminomethyl)-5-(2,4-dichlorophenyl)-7-methylimidazo[1,2-a]pyrimidine-2-carboxamides as potent, selective dipeptidyl peptidase-4 (DPP4) inhibitors.
Meng W; Brigance RP; Chao HJ; Fura A; Harrity T; Marcinkeviciene J; O'Connor SP; Tamura JK; Xie D; Zhang Y; Klei HE; Kish K; Weigelt CA; Turdi H; Wang A; Zahler R; Kirby MS; Hamann LG
J Med Chem; 2010 Aug; 53(15):5620-8. PubMed ID: 20684603
[TBL] [Abstract][Full Text] [Related]
16. Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Pei Z; Li X; von Geldern TW; Madar DJ; Longenecker K; Yong H; Lubben TH; Stewart KD; Zinker BA; Backes BJ; Judd AS; Mulhern M; Ballaron SJ; Stashko MA; Mika AK; Beno DW; Reinhart GA; Fryer RM; Preusser LC; Kempf-Grote AJ; Sham HL; Trevillyan JM
J Med Chem; 2006 Nov; 49(22):6439-42. PubMed ID: 17064063
[TBL] [Abstract][Full Text] [Related]
17. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Augeri DJ; Robl JA; Betebenner DA; Magnin DR; Khanna A; Robertson JG; Wang A; Simpkins LM; Taunk P; Huang Q; Han SP; Abboa-Offei B; Cap M; Xin L; Tao L; Tozzo E; Welzel GE; Egan DM; Marcinkeviciene J; Chang SY; Biller SA; Kirby MS; Parker RA; Hamann LG
J Med Chem; 2005 Jul; 48(15):5025-37. PubMed ID: 16033281
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.
Wiedeman PE; Trevillyan JM
Curr Opin Investig Drugs; 2003 Apr; 4(4):412-20. PubMed ID: 12808880
[TBL] [Abstract][Full Text] [Related]
19. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Kim D; Wang L; Beconi M; Eiermann GJ; Fisher MH; He H; Hickey GJ; Kowalchick JE; Leiting B; Lyons K; Marsilio F; McCann ME; Patel RA; Petrov A; Scapin G; Patel SB; Roy RS; Wu JK; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
J Med Chem; 2005 Jan; 48(1):141-51. PubMed ID: 15634008
[TBL] [Abstract][Full Text] [Related]
20. A triumph for physiology driving drug discovery: the potential impact of dipeptidyl peptidase-IV inhibitors in type 2 diabetes.
Donnelly R
Diabetes Obes Metab; 2007 Mar; 9(2):151-2. PubMed ID: 17300590
[No Abstract] [Full Text] [Related]
[Next] [New Search]
